
0:00
13:39
Normally used as a glucose-lowering agent in the treatment of type 2 diabetes, SGLT2 inhibitors have been found to have beneficial effects in patients with heart failure and kidney disease. Jo Cheah finds out more from cardiologist John Atherton.
More episodes from "Australian Prescriber Podcast"
Don't miss an episode of “Australian Prescriber Podcast” and subscribe to it in the GetPodcast app.